<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.rcuk.ac.uk/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/78308CAA-8483-45C0-A280-0AB4B6AD9D35"><gtr:id>78308CAA-8483-45C0-A280-0AB4B6AD9D35</gtr:id><gtr:name>Medical Research Council</gtr:name><gtr:address><gtr:line1>Polaris House</gtr:line1><gtr:line2>North Star Avenue</gtr:line2><gtr:postCode>SN2 1FL</gtr:postCode><gtr:region>South West</gtr:region></gtr:address></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.rcuk.ac.uk:80/organisation/3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9"><gtr:id>3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9</gtr:id><gtr:name>University of Oxford</gtr:name><gtr:department>Clinical Trial Service Unit</gtr:department><gtr:address><gtr:line1>University Chest</gtr:line1><gtr:line2>Wellington Square</gtr:line2><gtr:line4>Oxford</gtr:line4><gtr:postCode>OX1 2JD</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9"><gtr:id>3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9</gtr:id><gtr:name>University of Oxford</gtr:name><gtr:address><gtr:line1>University Chest</gtr:line1><gtr:line2>Wellington Square</gtr:line2><gtr:line4>Oxford</gtr:line4><gtr:postCode>OX1 2JD</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/78308CAA-8483-45C0-A280-0AB4B6AD9D35"><gtr:id>78308CAA-8483-45C0-A280-0AB4B6AD9D35</gtr:id><gtr:name>Medical Research Council</gtr:name><gtr:address><gtr:line1>Polaris House</gtr:line1><gtr:line2>North Star Avenue</gtr:line2><gtr:postCode>SN2 1FL</gtr:postCode><gtr:region>South West</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/3434EFD8-9DAC-49B9-9981-FD875519A53E"><gtr:id>3434EFD8-9DAC-49B9-9981-FD875519A53E</gtr:id><gtr:firstName>Richard</gtr:firstName><gtr:surname>Peto</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.rcuk.ac.uk:80/projects?ref=G0901509"><gtr:id>BABB4762-60E5-4793-A61B-74DD7ECB5A29</gtr:id><gtr:title>Completion of leukaemia trials</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>G0901509</gtr:grantReference><gtr:abstractText>Forty years ago almost nobody was cured of leukaemia. Nowadays, however, in countries such as the UK most children and young adults who develop the disease are completely cured, and they and their descendants will probably have no adverse late effects from it or its treatment. Although complete cure is less common among older leukaemia patients it is sometimes achieved, and even if the disease cannot be cured, prolonged remission with a good quality of life may nowadays be possible. 

Most of this progress has involved not huge breakthroughs that could easily be recognised as such, but a series of gradual improvements, each too small to be recognised reliably without large randomised trials in which half the patients got one treatment, half got another, and both groups of patients were then followed up for many years. Indeed, some moderate improvements in treatment could be reliably recognised as such only when there was worldwide collaboration between all who had ever conducted such a randomised trial of it. 
For many years the CTSU has coordinated nationwide UK leukaemia trials and the present application is to allow us to continue our involvement over the next 4 years. Leukaemia trials take far more than 4 years to complete, however, so the main results emerging over the next 4 years will be from trials that are already in progress among many hundreds, or even thousands, of patients, and from worldwide collaborations that the CTSU has already partly established, involving thousands or even tens of thousands of patients. Some of these studies, helped by the new genetic and other tests that are now becoming possible on the many thousands of stored samples from current and past MRC leukaemia trials, will probably show that some particular types of patient will gain net long-term benefit from more intensive treatment, and that other patients will not. Clear results from the CTSU can quickly change clinical practice, and could well save both lives and money.</gtr:abstractText><gtr:technicalSummary>Leukaemia trials: CTSU will continue over the next four years to provide long-term follow-up, data management, statistical analyses and trial expertise for previous, current and future studies. Maintaining previous and current trials (and sharing data from them) remains a core CTSU responsibility. During the next 4 years four more trials will reach the point where the treatment comparisons can be analysed and reported, but follow-up on these and previous studies will continue. The increasing range of novel genetic and other tests that is becoming possible on stored samples, in conjunction with clinical data, will continue to yield new findings.</gtr:technicalSummary><gtr:fund><gtr:end>2013-05-31</gtr:end><gtr:funder url="http://gtr.rcuk.ac.uk:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2009-06-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>993139</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>Medical Research Council (MRC)</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>MRC/Cancer Research UK/BHF Clinical Trial Service Unit &amp; Epidemiological Studies Unit</gtr:department><gtr:description>CTSU QQR</gtr:description><gtr:id>FDB45877-AE25-4C43-ADC6-D431967C3D3D</gtr:id><gtr:impact>Please see return for CTSU QQR

U137686856</gtr:impact><gtr:piContribution>Please see return for CTSU QQR

U137686856</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2008-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs/><gtr:exploitationOutputs/><gtr:furtherFundingOutputs/><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/CC48AD2C-E9FD-47CD-8CC1-E5AE8B4942C8"><gtr:id>CC48AD2C-E9FD-47CD-8CC1-E5AE8B4942C8</gtr:id><gtr:title>HLA-DP?1 Asp84-Lys69 antigen-binding signature predicts event-free survival in childhood B-cell precursor acute lymphoblastic leukaemia: results from the MRC UKALL XI childhood ALL trial.</gtr:title><gtr:parentPublicationTitle>Blood cancer journal</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/14c490a65dfdb359c8adc69864db1f2f"><gtr:id>14c490a65dfdb359c8adc69864db1f2f</gtr:id><gtr:otherNames>Taylor GM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>2044-5385</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/3BBF2973-C99A-4586-9BBA-87004BB059C4"><gtr:id>3BBF2973-C99A-4586-9BBA-87004BB059C4</gtr:id><gtr:title>Meta-analysis of randomised trials comparing thiopurines in childhood acute lymphoblastic leukaemia.</gtr:title><gtr:parentPublicationTitle>Leukemia</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/6ab45e2374bc8925368055e8466bd49d"><gtr:id>6ab45e2374bc8925368055e8466bd49d</gtr:id><gtr:otherNames>Escherich G</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0887-6924</gtr:issn></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">G0901509</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>7C58A707-1BF6-4573-A44F-30B271C80813</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Cancer</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>7135039D-2DB0-4D41-87B3-FA1C8D38E133</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>6.1  Pharmaceuticals</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>